DYN241018C12500
- 21.45
- 0.000.00%
Dyne Therapeutics Newsroom
Dyne Therapeutics Analyst Ratings
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Piper Sandler Sticks to Its Buy Rating for Dyne Therapeutics (DYN)
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $50 to $55
Dyne Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
Dyne Therapeutics Analyst Ratings
Buy Rating Affirmed Amidst Dose Adjustments and Promising Trial Results for Dyne Therapeutics
Stifel Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $66
Dyne Therapeutics Analyst Ratings
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $52 to $55
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Raises Price Target to $52
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $50 to $55
Dyne Therapeutics (DYN) Receives a Buy From Piper Sandler
Chardan Adjusts Price Target on Dyne Therapeutics to $50 From $42, Maintains Buy Rating
Buy Rating Affirmed for Dyne Therapeutics on Strong Financials and Promising Clinical Data
JPMorgan Adjusts Price Target on Dyne Therapeutics to $43 From $39, Maintains Overweight Rating
Dyne Therapeutics Analyst Ratings
Chardan Raises Price Target on Dyne Therapeutics to $42 From $31, Cites Additional Positive Data on DYNE-101, DYNE-251; Buy Rating Kept